• Explore /
  • Poster
  • / Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.

Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.

Abstract Poster

Authors

null

Thorsten Oliver Goetze

University Cancer Center Frankfurt, Institut für Klinisch-Onkologische Forschung and IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, Germany

Thorsten Oliver Goetze , Daniel Wilhelm Mueller , Mohammad-Reza Rafiyan , Dragan Kiselicki , Regina Eickhoff , Elke Jaeger , Salah-Eddin Al-Batran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT03252938

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3099)

DOI

10.1200/JCO.2020.38.15_suppl.3099

Abstract #

3099

Poster Bd #

163

Abstract Disclosures

Similar Posters

First Author: Thorsten Oliver Goetze

First Author: Daniel Wilhelm Mueller

First Author: Igor Tsaur

First Author: Jayesh Desai